Krishnansu S. Tewari

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Krishnansu S. Tewari, Michael W. Sill, Harry J. Long et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Nicoletta Colombo, Coraline Dubot, Domenica Lorusso et al. · New England Journal of Medicine · 2021 · 992 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson et al. · The Lancet · 2017 · 679 citations · Full text

Medicine, Gynecology, Oncology +6

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Robert L. Coleman, Mark F. Brady, Thomas J. Herzog et al. · The Lancet Oncology · 2017 · 602 citations · Full text

Medicine, Gynecology, Oncology +15

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro et al. · Journal of Clinical Oncology · 2019 · 483 citations · Full text

Medicine, Gynecology, Oncology +12